INTRODUCTION

Liquid biopsy, a noninvasive alternative to tissue biopsy, provides real-time monitoring of lung cancer via more frequent analysis of circulating biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).

Datar Cancer Genetics Limited offers Liquid biopsy, a noninvasive alternative to tissue biopsy, provides real-time monitoring of lung cancer via more frequent analysis of circulating tumor DNA (cfDNA).

ABOUT LIQUID BIOPSY FOR LUNG CANCER

Datar Cancer Genetics Limited offers a more comprehensive picture of the disease that may reflect the status of the disease better and thereby contribute to more personalized treatment than tissue analysis.

Features of Liquid biopsy for lung cancer

  • Non-invasive biopsy for lung cancer mutation analysis
  • Inadequacy of tumor tissue is no longer a problem for targeted therapy selection
  • Patients unfit for invasive biopsy can still avail benefit of targeted therapies
  • Addresses problem of tumor heterogeneity
  • Helps in real-time disease monitoring and tumor evolution tracking
  • Therapy failure, due to acquired resistance mutations, can be detected prior to clinical/radiological disease progression
  • Gives information about tumor burden and molecular residual disease
  • Helps to know presence of acquired resistance mutations
  • High sensitivity (96.4%) and specificity (100%)
  • ASCO 2016 endorsed a liquid biopsy for tumor mutation analysis with respect

FOR WHOM?

Tissue biopsy is not feasible / inadequate tissue

Tissue biopsy is not feasible

Acquired resistance mutations without repeating invasive tissue biopsy is to be detected

Early detection of recurrence is desired in patients who have completed the therapy

Current mutation profile of the tumor is to be determined in progressive disease

Tumor burden in real-time is determined

HOW IT WORKS?

Liquid biopsy provides insight into the real-time dynamics of lung cancer via analysis of circulating biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). These circulating markers in blood may contain cancer-associated materials from multiple disease sites in the body

How it will help you?

What Liquid biopsy for lung cancer can reveal?

FAQS

When is the test indicated?

– When tissue biopsy is not feasible or tissue is inadequate for mutation testing
– To detect acquired resistance mutations without repeating invasive tissue biopsy
– In progressive disease, to know current mutation profile of the tumor
– For early detection of recurrence, in patients who have completed the therapy
– To know tumor burden in real-time

What is the sample requirement?

10 mL blood is collected in special DCGL collection tubes for testing.

What is the usual turn around time?

We provide results in 10 business days from receipt of sample.

Which genes are analyzed in liquid biopsy for lung cancer?

SNV Genes: ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, TP53

Fusion Genes:ALK, RET, ROS1

CNA Genes:Met and exon 14 skipping